HARD NUMBERS: Penn's Fergus Couch evaluated the "actual prevelance of BRCA1 mutations" among 263 women with a family history of the disease. In the early days of the Human Genome Project, attention focused on rare disorders that strictly follow Mendel's laws of inheritance, recurring in predictable patterns within families. With many of these genes identified and mapped as the finish line nears, emphasis has shifted to genes that cause more common ills, particularly cancers, and the public has
 HARD NUMBERS: Penn's Fergus Couch evaluated the "actual prevelance of BRCA1 mutations" among 263 women with a family history of the disease. |
EDUCATION NEEDED: Johns Hopkins' Gloria Petersen found that many health care professionals misinterpret the results of genetic tests. The unexpected complexity of genetic testing technology is threatening its acceptance by consumers. "It is a very difficult situation. New discoveries attract publicity, and the ...
When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.
View this Issue
In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.
In this webinar, scientists will discuss innovations that are unlocking new insights into immunity.
In this webinar, Magdalena Pacewicz will highlight how to use AUC to characterize AAVs as part of ensuring regulatory compliance.
Discover how the latest cancer research models and their applications help scientists pursue breakthrough cancer therapy research.
Chief Business Officer Dr. Rob Burgess Shares How Sino Biological Is Empowering Global Biomedical Research Through Precision, Quality, and Innovation on an Exclusive Segment on Fox Business Network airing on February 1, 2026 at 4:30pm EST
Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.
Collaboration will bring next generation orchestration and modular automation to scientists worldwide
The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.
